Spruce Biosciences Inc Ordinary Shares SPRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPRB is a good fit for your portfolio.
News
-
Spruce Biosciences to Participate in May Investor Conferences
-
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
-
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
-
Attention Spruce Biosciences Investors: Company Investigated by the Portnoy Law Firm
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.73–0.76
- 52-Week Range
- $0.67–5.95
- Bid/Ask
- $0.73 / $0.76
- Market Cap
- $30.63 Mil
- Volume/Avg
- 503,654 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Comparables
Valuation
Metric
|
SPRB
|
CBAY
|
DYN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.40 | 12.65 | 4.75 |
Price/Sales | 2.84 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SPRB
CBAY
DYN
Financial Strength
Metric
|
SPRB
|
CBAY
|
DYN
|
---|---|---|---|
Quick Ratio | 3.94 | 10.70 | 2.41 |
Current Ratio | 4.18 | 10.96 | 2.53 |
Interest Coverage | −107.65 | −5.27 | — |
Quick Ratio
SPRB
CBAY
DYN
Profitability
Metric
|
SPRB
|
CBAY
|
DYN
|
---|---|---|---|
Return on Assets (Normalized) | −38.14% | −30.06% | −88.69% |
Return on Equity (Normalized) | −49.77% | −51.97% | −114.25% |
Return on Invested Capital (Normalized) | −51.22% | −30.87% | −102.56% |
Return on Assets
SPRB
CBAY
DYN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lwjcvsfth | Pxr | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gzzjgbswx | Nytzm | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bxqfvpyd | Twdqnw | $103.7 Bil | |
MRNA
| Moderna Inc | Zfrnyvcs | Fflc | $47.9 Bil | |
ARGX
| argenx SE ADR | Srmfcfpp | Hvb | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Tyntdsfm | Txkt | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Frhltbtb | Dnctz | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fbgrrqd | Slypkdn | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jgwnpcdks | Dzxjvhz | $12.8 Bil | |
INCY
| Incyte Corp | Rfbdkbmk | Bgdlszc | $12.1 Bil |